Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xupeng Hou
Observed name:
Hou, Xupeng
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Tianjin Medical University Cancer Institute and Hospital,
Fudan University Shanghai Cancer Center,
Tianjin Medical University
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Tianjin Medical University Cancer Institute and Hospital,
Fudan University Shanghai Cancer Center,
Tianjin Medical University
ORCID:
0009-0000-6330-1773
Observed ORCID:
0009-0000-6330-1773
OpenAlex ID:
A5048252551
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
2023
·
Tianxing Zhou
, Yongjie Xie
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
87
PDF
Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy
2024
·
Yongjie Xie
, Tianxing Zhou
, et al.
·
Gastroenterology
·
59
SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation
2023
·
Jing Liu
, Weiwei Bai
, et al.
·
Gut
·
44
Triple‐negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding
2024
·
Xupeng Hou
, Xueyang Li
, et al.
·
Cancer
·
32
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells
2024
·
Tianxing Zhou
, Xupeng Hou
, et al.
·
Gut
·
22
Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma
2023
·
Tianxing Zhou
, Quan Man
, et al.
·
Cancer Biology and Medicine
·
19
PDF
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy
2026
·
Jing Liu
, Xupeng Hou
, et al.
·
Gut
·
11
KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability
2024
·
Wenna Jiang
, Lin Liu
, et al.
·
Cellular and Molecular Life Sciences
·
8
PDF
The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
·
Cancer Research
·
7
Albumin-bound paclitaxel–induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer
2026
·
Haorui Li
, Xi Ma
, et al.
·
Science Translational Medicine
Abscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances
2026
·
Yihong Dong
, Moran Chen
, et al.
·
MedComm
PDF
Figure S9 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Table S8 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Figure S6 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Figure S2 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Figure S7 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Figure S1 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Figure S10 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Table S10 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Figure S4 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Table S1 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Figure S8 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Table S4 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Table S7 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Table S5 from The SDC1–ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment That Drives Tumor Radioresistance
2026
·
Xupeng Hou
, Moran Chen
, et al.
Show more works
View as search
Works count:
45
Citation count:
289
H-index:
8
I10-index:
7
Year
Topic
Type